JP Morgan Maintains Overweight on TransMedics Gr, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Allen Gong maintains an Overweight rating on TransMedics Group (TMDX) and raises the price target from $87 to $105.

February 27, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Allen Gong reaffirmed an Overweight rating on TransMedics Group and increased the price target from $87 to $105.
An increase in the price target by a reputable analyst such as JP Morgan's Allen Gong typically signals a strong bullish outlook on the stock, suggesting potential upside. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100